Price T Rowe Associates Inc Citius Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.6 - $0.9 $1,260 - $1,890	2,100 Added 7.47%	30,231 $28,000
Q4 2023 Feb 14, 2024	BUY	$0.65 - $0.86 $2,029 - $2,684	3,122 Added 12.48%	28,131 $22,000
Q3 2023 Nov 14, 2023	SELL	$0.65 - $1.25 $15,275 - $29,375	-23,500 Reduced 48.44%	25,009 $18,000
Q2 2023 Aug 14, 2023	BUY	$1.08 - $1.65 $27,009 - $41,264	25,009 Added 106.42%	48,509 $59,000
Q1 2023 May 15, 2023	BUY	$0.78 - $1.42 $858 - $1,562	1,100 Added 4.91%	23,500 $28,000
Q2 2022 Aug 15, 2022	BUY	$0.88 - $1.87 $1,312 - $2,788	1,491 Added 7.13%	22,400 $21,000
Q1 2022 May 16, 2022	BUY	$1.38 - $1.89 $4,554 - $6,237	3,300 Added 18.74%	20,909 $37,000
Q4 2021 Feb 14, 2022	SELL	$1.51 - $2.2 $3,020 - $4,400	-2,000 Reduced 10.2%	17,609 $27,000
Q3 2021 Nov 15, 2021	BUY	$1.74 - $2.6 $1,044 - $1,560	600 Added 3.16%	19,609 $40,000
Q2 2021 Aug 16, 2021	BUY	$1.51 - $4.23 $12,999 - $36,416	8,609 Added 82.78%	19,009 $66,000
Q4 2020 Feb 16, 2021	BUY	$0.9 - $1.2 $9,360 - $12,480	10,400 New	10,400 $11,000

30.6M

24.7K

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $73.1M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.